Published by Josh White on 31st October 2024
(Sharecast News) - Pharmaceuticals firm Merck reported a solid third quarter on Thursday, with revenue up 4% year-over-year to $16.7bn, driven by robust sales of its cancer drug Keytruda, although muted demand for the Gardasil HPV vaccine remained a challenge.
URL: http://www.digitallook.com/dl/news/story/34662256/...